NuvOx Therapeutics (NUOX) sets $6 to $8 IPO price range for NYSE American debut
As seen on the 24/7 Wall St. homepage on September 16, 2026.
Price range set at $6 to $8 in first S-1 amendment
NuvOx Therapeutics put real numbers on its NYSE American debut: 2.86 million shares at $6 to $8, or about $20 million at the midpoint, with ThinkEquity running the book. The clinical-stage oxygen therapeutics developer is now one pricing amendment away from trading.
Continue ReadingShow less
NuvOx Therapeutics has filed its first S-1 amendment, locking in a price range of $6 to $8 per share for its planned NYSE American listing.
ThinkEquity is running the book on the offering. For a clinical-stage company, the choice of bookrunner and the size of the raise matter: $20 million sets a concrete ceiling on how much runway NuvOx can add from this transaction alone.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The amended filing moves NuvOx one formal step closer to trading. Under the typical IPO process, the company now enters the roadshow and pricing window, after which a final price is set and shares begin trading on NYSE American.
Investors eyeing the deal should keep a close watch on where within the $6 to $8 range the final price lands, since pricing at the top would signal stronger-than-expected institutional demand for an oxygen therapeutics developer at this stage of development.
Mentioned: NUOX